Synta Pharmaceuticals Corp., of Lexington, Mass., entered common stock purchase agreements with investors for the sale of 7.2 million shares of common stock in an issuer-directed registered direct offering

Through an asset purchase agreement, GliaMed will be eligible to receive up to 8,205 shares of newly designated Series E Preferred Stock, convertible into approximately 20 percent of La Jolla's fully diluted outstanding common stock on an as-converted basis

entered a share purchase agreement with D.N.A Biomedical Solutions Ltd., of Rishon, Israel, for the

entered a share purchase agreement with D.N.A Biomedical Solutions Ltd., of Rishon, Israel, for the sale of most of its holdings in Entera Bio Ltd., for $1.15 million, and a commitment by D.N.A to invest $250,000 in Oramed

NovaDel Pharma Inc., of Bridgewater, N.J., entered a securities purchase agreement to raise $1.6 million in gross proceeds through the sale of 1,667 shares of Series A convertible preferred stock to institutional investors

Details (Date) Acadia Pharmaceuticals Inc. (San Diego) Private placement of units 12.57U $15 Acadia raised $15M in a private placement from New Enterprise Associates and Venrock (1/11) Adeona Pharmaceuticals Inc. (Ann Arbor, Mich.) Private placement of common stock and warrants 2.85S and W for 1.42S $4 Adeona raised $4M through the sale (1/31) Advanced Cell Technology Inc. (Marlborough, Mass.) Nonconvertible stock purchase agreement 0.0004S $4 Socius CG II Ltd

4SC AG, of Planegg-Martinsried, Germany, dosed the first patient in its Phase I/II SHORE study of oral pan-histone deacetylase inhibitor resminostat in second-line advanced and metastatic colorectal KRAS-mutant cancer. The 70-patient trial will test the drug in combination with chemotherapy regimen FOLFIRI vs. FOLFIRI alone. The primary endpoint will be progression-free survival (PFS), while secondary endpoints will measure PFS rate after eight weeks and every eight weeks thereafter, time to

The investment is pursuant to a 2009 Securities Purchase Agreement, and will leave Teva with 6.29 percent ownership in Rexahn.

The investment is pursuant to a purchase agreement and follows development milestones achieved by Calando, including proof of siRNA delivery and RNAi knockdown of human targets

the funding gives Crucible a post-money valuation of $14M (12/3) Curaxis Pharmaceutical Corp. (OTC BB:CURX) Equity purchase agreement 14.5S $10.7 Curaxis agreed to a $25M equity purchase and line of credit agreement with Southridge Partners II

Biotech Company (Country; Symbol) Action Taken Details (Date)# Accentia Biopharmaceuticals Inc. (PK:ABPIQ) Company filed a proposed reorganization plan with the U.S. Bankruptcy Court for the Middle District of Florida, Tampa Division; successfully completed its reorganization Accentia expects to emerge from Chapter 11 bankruptcy this summer as a fully restructured company (6/2); Accentia and its subsidiary, Biovest (See Biovest below), said the plan of reorganization was confirmed, and the

Under a separate purchase agreement, Lincoln Park committed to purchasing up to $11 million of RegeneRx stock over a 30-month period

January | February | March | April | May | June | July | August | September | October | November | December | December - 2011 Biotech Company Pharma Company Type/Product Area Terms/Details Akorn Inc. H. Lundbeck A/S Akorn's subsidiary, Oak Pharmaceuticals, acquired three off-patent, branded, hospital-based injectables Akorn will make an up-front payment of $45M and a subsequent milestone payment of $15M in cash after three years Amgen Inc. Watson Pharmaceuticals Inc. Deal to develop

January | February | March | April | May | June | July | August | September | October | November | December | December - 2011 Company Company Type/Product Area Terms/Details Ampio Pharmaceuticals Inc. Undisclosed party Deal to acquire rights to a patented orally disintegrating tablet drug delivery technology for use with Zertane, its candidate for premature ejaculation Financial terms were not disclosed AtheroNova Inc. OOO CardioNova (Russian subsidiary of Maxwell Biotech

Equity purchase agreement N/A (up to $20) BiOasis Technologies Inc...Purchase agreement 0.9S (up to $20) PharmaGap Inc

Advanced Cell Technology Inc., of Marlborough, Mass., entered into a $25 million nonconvertible stock purchase agreement with Socius CG II Ltd., a subsidiary of Socius Capital Group, of New York and Los Angeles

Nutra would not receive any of these proceeds but might receive $10 million under a separate purchase agreement with Lincoln

served as placement agents for the financing (11/18) Marina Biotech Inc. (MRNA) Securities purchase agreement 1.8S $8.7 Marina sold 1.8M shares at $1.84 per share to raise $8.7M

Earlier this month, the company announced that it entered an asset purchase agreement under which Sekisui Chemical Co